In this presentation from the ESMO 18th World Congress on Gastrointestinal Cancer, Dr. Thomas Seufferlein argues that it is not justified to move from adjuvant to neo-adjuvant treatment in the treatment of pancreatic cancer.
Controversy Debate 1: Is it justified to move from adjuvant to neo-adjuvant treatment? – No
